<DOC>
	<DOCNO>NCT00923715</DOCNO>
	<brief_summary>The purpose study determine whether exenatide pramlintide improve blood glucose control meal compare insulin alone .</brief_summary>
	<brief_title>Exenatide ( Byetta ) Versus Pramlintide ( Symlin ) : Role Post-Prandial Hyperglycemia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>1 . Age 12 21 year . 2 . HbA1C le 9 % 3 . Subjects must intensive insulin management 4 . Cpeptide le 0.3 ng/ml 5 . Tanner stage great equal 3 6 . Having T1DM least one year 7 . T1DM define ADA criterion least one follow antibody a. AntiGAD ( glutamic acid decarboxylase ) b. Antiislet cell 512 ( ICA512 ) c. Antiinsulin 8 . Willing give consent . 1 . Type 2 diabetes . 2 . Having chronic condition except hypothyroidism stable medication . 3 . On chronic medication may affect glucose excursion . 4 . Anemia define Hb le 9 gm/dl . 5 . Abnormal AST , ALT , amylase , lipase creatinine ( twice normal ) . 6 . Unsupportive family environment determine clinician and/or social worker . 7 . Pregnant lactating mother</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Pramlintide</keyword>
</DOC>